218 related articles for article (PubMed ID: 12017345)
21. Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Bliesath H; Simon B; Hartmann M; Müller P; Schneider A; Lühmann R; Wurst W
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):439. PubMed ID: 1337063
[No Abstract] [Full Text] [Related]
22. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
23. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
24. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
25. Restoration of acid secretion following treatment with proton pump inhibitors.
Shin JM; Sachs G
Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
[TBL] [Abstract][Full Text] [Related]
26. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
27. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
[TBL] [Abstract][Full Text] [Related]
28. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
Sachs G; Shin JM; Pratha V; Hogan D
Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
[TBL] [Abstract][Full Text] [Related]
29. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs.
De Graef J; Woussen-Colle MC
Gastroenterology; 1986 Aug; 91(2):333-7. PubMed ID: 2873074
[TBL] [Abstract][Full Text] [Related]
30. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
31. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
32. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Fitton A; Wiseman L
Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
[TBL] [Abstract][Full Text] [Related]
33. Pantoprazole: a new proton pump inhibitor.
Jungnickel PW
Clin Ther; 2000 Nov; 22(11):1268-93. PubMed ID: 11117653
[TBL] [Abstract][Full Text] [Related]
34. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
Morozov IA
Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
[TBL] [Abstract][Full Text] [Related]
35. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Metz DC
Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitors: new drugs and indications.
Mears JM; Kaplan B
Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
[TBL] [Abstract][Full Text] [Related]
37. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
38. Gastroprotective effects of pantoprazole against experimental mucosal damage.
Blandizzi C; Natale G; Gherardi G; Lazzeri G; Marveggio C; Colucci R; Carignani D; Del Tacca M
Fundam Clin Pharmacol; 2000; 14(2):89-99. PubMed ID: 10796055
[TBL] [Abstract][Full Text] [Related]
39. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
[TBL] [Abstract][Full Text] [Related]
40. Pantoprazole.
Poole P
Am J Health Syst Pharm; 2001 Jun; 58(11):999-1008. PubMed ID: 11402494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
